IDH1 and oligodendroglioma: IDH-mutant astrocytomas exhibit a comparatively higher responsiveness to checkpoint immunotherapy compared to IDH-mutant oligodendrogliomas, primarily due to the reduced expression of PD-L1 and other checkpoint molecules in the latter.